10-Q: Aclarion Q3 2025: Revenue Jumps, Capital Secured, Losses Mount

Aclarion, Inc. reported a 61.3% revenue increase for the nine months ended September 30, 2025, driven by UK market expansion, while securing over $20 million in capital to extend its operational runway through Q1 2027 despite rising operating losses.

Summary

• Revenue for the nine months ended September 30, 2025, increased by 61.3% to $57,251, compared to $35,492 for the same period in 2024, primarily due to growing NOCISCAN report volumes in the UK market.
• The company's gross profit significantly improved to $5,037 for the nine months ended September 30, 2025, from a gross loss of $(28,610) in the prior year.
• Operating expenses rose by 37.7% to $5,064,434 for the nine months ended September 30, 2025, compared to $3,678,217 in 2024, driven by increased sales and marketing, research and development, and general and administrative costs.
• Net loss for the nine months ended September 30, 2025, increased to $(5,344,487) from $(5,003,355) in the comparable period of 2024.
• Cash and cash equivalents stood at $11,341,336 as of September 30, 2025, a substantial increase from $453,661 at December 31, 2024.
• The company raised aggregate gross proceeds of $20,058,913 through public and registered direct offerings and warrant exercises during the nine months ended September 30, 2025.
• Subsequent to the quarter, in October 2025, an additional $2.5 million in gross proceeds was raised through a registered direct public offering.
• Current cash is expected to fund operating expenses and capital expenditure requirements through the first quarter of 2027.
• Material weaknesses in internal control over financial reporting were identified as of December 31, 2024, related to limited segregation of duties and inadequate accounting resources for complex transactions.

Sentiment

Score: 4

Explanation: The company shows positive revenue growth and has successfully secured significant capital, extending its operational runway. However, it continues to incur substantial and increasing net losses and operating expenses, coupled with identified material weaknesses in internal controls. The ongoing need for further capital raises and the high cash burn rate present significant risks, balancing out the positive developments.

Positives

• Total revenues increased by 61.3% for the nine months ended September 30, 2025, reaching $57,251, driven by UK market expansion.
• Gross profit improved significantly to $5,037 for the nine months ended September 30, 2025, compared to a gross loss of $(28,610) in the prior year.
• Cash and cash equivalents increased substantially to $11,341,336 as of September 30, 2025, from $453,661 at December 31, 2024.
• Successfully raised over $20 million in gross proceeds from equity offerings and warrant exercises during the nine months ended September 30, 2025, and an additional $2.5 million in October 2025.
• The capital raises have extended the company's operational runway through the first quarter of 2027.
• Total liabilities decreased to $699,747 as of September 30, 2025, from $1,153,426 at December 31, 2024, partly due to debt retirement.

Negatives

• Net loss increased to $(5,344,487) for the nine months ended September 30, 2025, from $(5,003,355) in the prior year.
• Loss from operations increased to $(5,059,397) for the nine months ended September 30, 2025, from $(3,706,827) in the prior year.
• Operating expenses increased by 37.7% to $5,064,434 for the nine months ended September 30, 2025.
• Net cash used in operating activities increased to $(5,536,766) for the nine months ended September 30, 2025, indicating a higher cash burn.
• The company paid $687,500 in March 2025 to settle a dispute under an investment banking agreement, resulting in a net penalty of $672,500.
• Material weaknesses in internal control over financial reporting were identified as of December 31, 2024, due to limited segregation of duties and inadequate accounting resources.

Risks

• Limited operating history and early stage of development.
• Competition from other companies in the healthcare technology sector.
• Limited access to additional funds and the need to raise substantial additional capital to achieve business objectives.
• Dependence on key personnel.
• Challenges in managing potential rapid growth.
• Inability to guarantee that future results, levels of activity, performance, or events and circumstances reflected in forward-looking statements will be achieved.
• Risk of dilution for existing stockholders if additional capital is raised through equity sales.
• Potential for restrictive covenants in debt or preferred equity financing agreements.
• Inability to generate meaningful revenues from medical technology products, which is a time-consuming, expensive, and uncertain process.

Future Outlook

Management expects the increase in revenue from NOCISCAN reports to continue as more insurance payors are brought on and scan volumes increase. Research and development expenses are anticipated to continue increasing in coming quarters as enrollment in the CLARITY Trial expands. The company will need to raise additional funds to continue funding technology development and commercialization efforts beyond the first quarter of 2027.

Management Comments

• We expect this increase in revenue to continue as we bring on more insurance payors, and our scan volumes increase.
• We expect to see research and development expenses to continue to increase in the coming quarters as our enrollment in the CLARITY Trial continues to expand.
• We believe our current cash will fund our operating expenses and capital expenditure requirements through the first quarter of 2027.
• Management is actively managing our cash position and continually working to secure additional long-term funding.

Industry Context

Aclarion operates in the healthcare technology sector, leveraging magnetic resonance spectroscopy (MRS) with proprietary biomarkers to optimize clinical treatments. As an early-stage company, it faces typical challenges including limited operating history, intense competition, and the need for continuous funding for technology development and commercialization. The expansion into the UK market with NOCISCAN reports, following local coverage decisions, indicates progress in market penetration and reimbursement, aligning with broader trends of adopting innovative diagnostic tools in healthcare.

Management Changes

Corporate Governance

Legal Proceedings

• Paid $687,500 in March 2025 to settle a dispute under the 'fee tail' provision of an investment banking agreement, netted against a $15,000 favorable accounts payable settlement, resulting in a net expense of $672,500.

Stakeholder Impact

• Shareholders face significant dilution from multiple equity offerings and warrant exercises, but benefit from an extended operational runway.
• Employees are impacted by share-based compensation and bonus accruals.
• Customers in the UK market benefit from expanded availability of NOCISCAN reports following local coverage decisions.
• Creditors benefit from the retirement of unsecured non-convertible notes in 2024.
• The Regents of the University of California receive royalty payments under an exclusive license agreement.

Next Steps

• Continue market development and clinical evidence efforts.
• Advance product development and quality initiatives.
• Provide general and administration support.
• Expand enrollment in the CLARITY Trial.
• Secure additional long-term funding to continue technology development and commercialization efforts beyond Q1 2027.
• Work with an outside firm to establish best practices to improve internal control over financial reporting.

Key Dates

Recommendation

Aclarion is an early-stage healthcare technology company demonstrating strong revenue growth in its Nociscan reports, particularly in the UK market. The company has successfully raised substantial capital, extending its operational runway through Q1 2027, which is crucial for its continued development and commercialization efforts. However, this funding comes at the cost of significant shareholder dilution. The company continues to incur substantial net losses and increased operating expenses, reflecting its early development stage and high cash burn from operations. Furthermore, identified material weaknesses in internal controls present a governance concern. While the revenue trajectory is positive, the path to profitability remains distant and requires further capital. For existing investors, holding the stock allows for observation of continued market penetration and clinical trial progress, balanced against the ongoing financial challenges and governance risks.

Keywords

Aclarion, ACON, 10-Q, Quarterly Report, Healthcare Technology, Magnetic Resonance Spectroscopy, MRS, Nociscan, Medical Device, Diagnostics, SEC Filing, Financial Results, Capital Raise, Stock Split, Clinical Trial, Clarity Trial, Corporate Governance